Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | VCP | P55072 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12009933 | 0.90 | ADORA2A (0.32) | ADORA2AMEN1ALDH1A1LMNACYP3A4 | |
| SCHEMBL12009975 | 0.88 | ADORA2A (0.32) | ADORA2A | |
| SCHEMBL13819446 | 0.87 | MEN1 (0.33) | ADORA2AMEN1ALDH1A1LMNACYP3A4 | |
| SCHEMBL8932177 | 0.86 | ADORA2A (0.41) | ADORA2AMEN1ALDH1A1LMNACYP3A4 | |
| SCHEMBL13819448 | 0.86 | MEN1 (0.33) | ADORA2AMEN1ALDH1A1LMNACYP3A4 | |
| SCHEMBL8932187 | 0.85 | ADORA2A (0.35) | ADORA2AMEN1ALDH1A1LMNACYP3A4 | |
| SCHEMBL13819213 | 0.84 | MEN1 (0.32) | ADORA2AMEN1ALDH1A1LMNACYP3A4 | |
| SCHEMBL13819444 | 0.84 | MEN1 (0.34) | ADORA2AMEN1ALDH1A1LMNACYP3A4 | |
| SCHEMBL13625892 | 0.84 | GRIN2B (0.40) | CYP3A4SMN1; SMN2 | |
| SCHEMBL8932185 | 0.83 | GRIN2B (0.41) | ADORA2AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252767-B2 | Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists | DOGWOOD PHARMACEUTICALS, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| US-20110003765-A1 | SUBSTITUTED 4--PIPERIDINE-1-CARBOXYLIC ACID ESTERS AS A2AR AGONISTS | ADENOSINE THERAPEUTICS, LLC | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003765-A1 | SUBSTITUTED 4--PIPERIDINE-1-CARBOXYLIC ACID ESTERS AS A2AR AGONISTS | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885MEN1 4026/4885ALDH1A1 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.